Skip to content
Peptigraph home

TRIUMPH-3: Retatrutide Phase 3 trial (NCT05882045)

A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
1,946
actual
Start
30 May 2023 (actual)
Primary completion
16 Apr 2026 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05882045 study arms
ArmTypeInterventionsDescription
Retatrutide Dose 1ExperimentalDrug: RetatrutideParticipants will receive retatrutide subcutaneously (SC).
Retatrutide Dose 2ExperimentalDrug: RetatrutideParticipants will receive retatrutide SC.
PlaceboPlacebo comparatorDrug: PlaceboParticipants will receive placebo.
Endpoints

Primary endpoint

NCT05882045 primary outcomes
MeasureTime frame
Percent Change from Baseline in Body WeightBaseline, Week 80
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05882045 secondary outcomes
MeasureTime frame
Change from Baseline in Body Mass Index (BMI)Baseline, Week 80
Change from Baseline in Waist CircumferenceBaseline, Week 80
Percent Change from Baseline in Total CholesterolBaseline, Week 80
Percent Change from Baseline in TriglyceridesBaseline, Week 80
Change from Baseline in Systolic Blood Pressure (SBP)Baseline, Week 80
Change from Baseline in Diastolic Blood Pressure (DBP)Baseline, Week 80
Change from Baseline in Hemoglobin A1c (HbA1c)Baseline, Week 80
Percent Change from Baseline in Fasting InsulinBaseline, Week 80
Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain ScoreBaseline, Week 80
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC)Baseline to Week 80
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular DiseaseClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.